DOCSLIB.ORG

(2,6-Dimethylaniline) (CASRN 87-62-7) in Charles River CD Rats

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(2,6-Dimethylaniline) (CASRN 87-62-7) in Charles River CD Rats NATIONAL TOXICOLOGY PROGRAM Technical Report Series No. 278 TOXICOLOGY AND CARCINOGENESIS STUDIES OF 2,6=XYLIDINE (2,6-DIMETHYLANILINE) (CAS NO. 87-62-7) IN CHARLES RIVER CD RATS (FEED STUDIES) U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health FOREWORD The National Toxicology Program (NTP) is made up of four charter agencies of the U.S.Department of Health and Human Services (DHHS): the National Cancer Institute (NCI), National Institutes of Health the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health; the National Center for Toxicological Research (NCTR), Food and Drug Administration; and the National Institute for Occupational Safety and Health (NIOSH), Centers for Disease Control. In July 1981, the Carcinogenesis Bioassay Testing Program, NCI, was transferred to the NIEHS. The NTP coordinates the relevant programs, staff, and resources from these Public Health Service agen- cies relating to basic and applied research and to biological assay development and validation. The NTP develops, evaluates, and disseminates scientific information about potentially toxic and hazardous chemicals. This knowledge is used for protecting the health of the American people and for the primary prevention of disease. The studies described in this Technical Report were performed under the direction of the NIEHS and were conducted in compliance with NTP chemical health and safety requirements and must meet or exceed all applicable Federal, state, and local health and safety regulations. Animal care and use were in accordance with the Public Health Service Policy on Humane Care and Use of Animals. All NTP toxicology and carcinogenesis studies are subjected to a comprehensive audit before being pre- sented for public review. This Technical Report has been reviewed and approved by the NTP Board of Scientific Counselors’ Peer Review Panel in public session; the interpretations described herein rep resent the official scientific position of the NTP. These studies are designed and conducted to characterize and evaluate the toxicologic potential, in- cluding carcinogenic activity, of selected chemicals in laboratory animals (usually two species, rats and mice). Chemicals selected for NTP toxicology and carcinogenesis studies are chosen primarily on the bases of human exposure, level of production, and chemical structure. Selection per se is not an indicator of a chemical’s carcinogenic potential. These NTP Technical Reports are available for sale from the National Technical Information Service, U.S. Department of Commerce, 5285 Port Royal Road, Springfeld, VA 22161 (703-487-4650). Single copies of this Technical Report are available without charge while supplies last from the NTP Public Information Office, NIEHS, P.O. Box 12233, Research Triangle Park, NC 27709 (919-541-3991). Special Note: This Technical Report underwent peer review in public session and was approved by the NTP Board of Scientific Counselors’ Technical Reports Review Subcommittee on September 22, 1982 [see pages 7-81. Thereafter, the NTP adopted the policy that the experimental data and labora- tory records from all NTP toxicology and carcinogenesis studies not yet printed and distributed would be audited. [A summary of the data audit is presented in Appendix G.1 Consequently, printing and distribution of this Technical Report have been delayed, and the format differs from that of Technical Reports that underwent peer review more recently. The categories of evidence of carcinogenicity adopted by the NTP in June 1983 were not used to evaluate these data. This final Technical Report supersedes all previous &afts of this report which have been distributed. 2,6-Xylidine, NTP TR 278 NTP TECHNICAL REPORT ON THE TOXICOLOGY AND CARCINOGENESIS STUDIES OF 2,6=XYLIDINE (2,6-DIMETHYLANILINE ) (CAS NO. 87-62-7) IN CHARLES RIVER CD RATS (FEED STUDIES) Mary Kornreich, Ph.D., and Charles A. Montgomery, Jr., D.V.M., Study Scientists NATIONAL TOXICOLOGY PROGRAM P.O. Box 12233 Research Triangle Park, NC 27709 January 1990 NTP TR 278 NIH Publication No. 90-2534 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health CONTENTS PAGE ABSTRACT ................................................................ 3 CONTRIBUTORS ............................................................ 5 PEERREVIEWPANEL ........................................................ 6 SUMMARY OF PEER REVIEW COMMENTS ......................................... 7 I. INTRODUCTION ........................................................ 9 II. MATERIALS AND METHODS .............................................. 13 III. RESULTS ............................................................. 25 IV. DISCUSSION AND CONCLUSIONS ........................................... 47 V . REFERENCES ......................................................... 53 APPENDIXES APPENDIX A SUMMARY OF LESIONS IN MALE CD RATS IN THE TWO-YEAR FEED STUDY OF 2.0-XYLIDINE ................................................ 59 APPENDIX B SUMMARY OF LESIONS IN FEMALE CD RATS IN THE TWO-YEAR FEED STUDY OF2.&XYLIDINE ................................................ 85 APPENDIX C MUTAGENICITY OF 2. &XYLIDINE IN SALMONELLA TYPHlMURlUM .............. 111 APPENDIX D CHEMICAL CHARACTERIZATION OF 2.6-XYLIDINE ....................... 115 APPENDIX E CHARACTERIZATION OF FORMULATED DIETS ......................... 125 APPENDIX F ANALYSIS OF FORMULATED DIETS .................................. 129 APPENDIX G AUDIT SUMMARY ............................................... 137 2.6.Xylidine. NTP TR 278 2 2,6-XYLIDINE (2,6-DIMETHYLANILINE) CAS NO.87-62-7 ABSTRACT 2,6-Xylidine is a chemical intermediate used principally in the production of dyes. It is also a com- ponent of tobacco smoke, a degradation product of aniline-based pesticides, and a metabolite of cer- tain drugs, particularly the xylide group of local anesthetics. The National Toxicology Program (NTP) sponsored single-administration, 2-week, and 13-week studies of 2,6-xylidine by gavage in F344/N rats. The U.S.Environmental Protection Agency (EPA) sponsored short-term gavage studies and 10-week range-finding feed studies in Charles River CD rats (a Sprague Dawley-derived strain). A carcinogenesis study of 2,6-xylidine was initiated by the EPA, which designed and monitored the study during the 2-year exposure period. The NTP then assumed responsibility for the study, con- ducting terminal kill, necropsy, histopathologic evaluation, data analysis, and report preparation. Oral LD50 values of 1.2-1.3 g/kg were calculated for F344/N and Charles River CD rats administered single doses of 2,6-xylidine. Marginally toxic effects occurred in the hepatic, renal, and hematopoietic systems of dosed rats in the single-.administration, 2-week, 10-week, and 13-week studies. The 56 male and 56 female Charles River CD rats used in the 104-week carcinogenesis studies were the offspring of animals fed diets containing 0, 300, 1,000, or 3,000 ppm 2,6-xylidine before breeding, during pregnancy, and through the lactation period. The concentrations of 2,6-xylidine offered to ani- mals in the 104-week studies were the same as those given to their parents. During most of the 2-year studies, high dose male and female rats showed a reduction (greater than 10%) in body weight gain. Survival in high dose male rats was significantly reduced (P<O.OOl) rela- tive to that in controls. Survival also was reduced in the 1,000-ppm group. There was no significant relationship between concentration and mortality in female rats, but mortality was high for all groups of female rats during the second year of the study. The epithelium of the nasal cavity was the primary site of compound-related neoplastic and nonneo- plastic lesions. The incidences of both papillomas and carcinomas of the nasal cavity were signifi- cantly increased in high dose male and female rats. Carcinomas or adenocarcinomas (combined) occurred in 28/56 high dose males, 24/56 high dose females, and 1/56 mid dose females. Papillary ade- nomas occurred in 10156 high dose males, 2/56 mid dose males, and 6/56 high dose females. None occurred in the other groups. The carcinomas were highly invasive and frequently destroyed the nasal turbinates and nasal septum. Metastasis to the brain was present in 5/56 male and 7/56 female high dose rats. Malignant mesenchymal tumors were observed in the nasal cavity. Rhabdomyosarcomas occurred in two high dose male rats and two high dose female rats. These rare malignant tumors have not been previously reported at this site in Sprague Dawley rats. Malignant mixed tumors having features of adenocarcinomas and rhabdomyosarcomas were reported in one high dose male and one high dose 3 2,6-Xylidine, NTP TR 278 female rat. One undifferentiated sarcoma was seen in a high dose female rat. The nonneoplastic le- sions observed in the nasal cavity included acute inflammation, epithelial hyperplasia, and squamous metaplasia. The incidences of subcutaneous tissue fibromas were increased in high dose male and female rats (male: control, 0156; low dose, 1/56; mid dose, 2/56; high dose, 4/56; female: 0156; 2/56; 1/56; 4/56) and were dose related. Subcutaneous fibrosarcomas were observed in three high dose females, one high dose male, one mid dose female, one low dose male, and one control female. A significant dose-related increase occurred in the incidence of female rats with neoplastic nodules of the liver (0156; 1/56; 2/56; 4/55). This increase was significant
Load more

Recommended publications
  • Synthesis and Toxicity
    Molecules 2008, 13, 986-994 molecules ISSN 1420-3049 © 2008 by MDPI www.mdpi.org/molecules Full Paper Fluorinated Analogs of Malachite Green: Synthesis and Toxicity George A. Kraus 1,*, Insik Jeon 1, Marit Nilsen-Hamilton 2, Ahmed M. Awad 2, Jayeeta Banerjee 2 and Bahram Parvin 3 1 Iowa State University Department of Chemistry, Ames, IA 50011, USA; Tel. +1 515-294-7794; Fax: +1 515-294-0105 2 Iowa State University Department of Biochemistry, Biophysics and Molecular Biology, Ames, IA 50011, USA; Tel. +1 515-9996; Fax: +1 515-294-0453 3 Lawrence Berkeley Laboratory Department of Cancer Biology, Berkeley, CA 94720, USA; Tel. +1 510-486-6203; Fax: +1 510-486-6363 * Author to whom correspondence should be addressed; E-mail: [email protected] Received: 21 March 2008; in revised form: 22 April 2008 / Accepted: 22 April 2008 / Published: 27 April 2008 Abstract: A series of fluorinated analogs of malachite green (MG) have been synthesized and their toxicity to Saccharomyces cerevisiae and a human ovarian epithelial cell line examined. The toxicity profiles were found to be different for these two species. Two analogs, one with 2,4-difluoro substitution and the other with 2-fluoro substitution seem to be the most promising analogs because they showed the lowest toxicity to the human cells. Keywords: Malachite Green; Malachite Green analogs; Bathochromic shift; Toxicity; Saccharomyces cerevisiae; human ovarian epithelial cells. Introduction We are developing a new procedure for real-time imaging of gene expression. It involves a nucleic acid probe that can be used in conjunction with a 18F-labeled target molecule to image gene expression in vivo [1].
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • 2,6-Dimethylaniline
    2,6-DIMETHYANILINE (2,6-XYIDINE) 1. Exposure Data 1.1 Chemical and physical data 1.1.1 Synonyms, structural and molecular data Chem. Abstr. SelV Reg. No.: 87-62-7 Chem. Abstr. Name: 2,6-Dimethylbenzenamine IUPAC Systematic Name: 2,6-Xylidine Synonyms: 1 -Ami no- 2,6-dimethylbenzene; 2-amino- 1,3-dimethylbenzene; 2-amino- 1,3-xylene; 2-amino-meta-xylene; 2,6-dimethylphenylamine; ortho-xylidine; 2,6-meta- xylidine; 2,6-xylylamine ~3NH' CHs CgHiiN MoL. wt: 121.18 1.1.2 Chemical and physical properties of the pure substance (a) Description: Clear liquid (Ethyl Corp., 1990); pungent odour (Ethyl Corp., 1991) (b) Boiling-point: 1'14 °c at 739 mm Hg (98.5 kPa) (Lide, 1991) (c) Melting-point: 11.2 °c (Lide, 1991) (d) Density: 0.9842 at 20°C (Lide, 1991) (e) Spectroscopy data: Infrared, ultraviolet and nucIear magnetic resonance speGtral data have been reported (Sadtler Research Laboratories, 1980; Pouchert, 1981, 1983; Sadtler Research Laboratories, 1991). if Solubility: Slightly soluble in water (7.5 g/l at 20°C); soluble in ethanol and diethyl ether (Hoechst Celanese Corp., 1989; lide, 1991) (g) Volatility: Vapour pressure, 0.125 mm Hg (17 Pa) at 25 ° C; 1 mm Hg (133 Pa i at 44°C (Chao et aL., 1983; lide, 1991) (h) Stabilty: Sensitive to air oxidation and light; inflammable (Hoechst Celanese Corp., 1989) -323- 324 IARC MONOGRAHS VOLUME 57 (i) Conversion factor: mg/m3 = 5.0 x ppm1 1. 1.3 Trade names, technical products and impurities 2,6-Dimethylaniline is available commercially at purities ranging from 98 to 99.6%, with xylenol as a tyical impurity (Hoechst Celanese Corp., 1989; Ethyl Corp., 1991).
    [Show full text]
  • Properties and Units in Clinical Pharmacology and Toxicology
    Pure Appl. Chem., Vol. 72, No. 3, pp. 479–552, 2000. © 2000 IUPAC INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE SCIENTIFIC DIVISION COMMITTEE ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)# and INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY CHEMISTRY AND HUMAN HEALTH DIVISION CLINICAL CHEMISTRY SECTION COMMISSION ON NOMENCLATURE, PROPERTIES, AND UNITS (C-NPU)§ PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES PART XII. PROPERTIES AND UNITS IN CLINICAL PHARMACOLOGY AND TOXICOLOGY (Technical Report) (IFCC–IUPAC 1999) Prepared for publication by HENRIK OLESEN1, DAVID COWAN2, RAFAEL DE LA TORRE3 , IVAN BRUUNSHUUS1, MORTEN ROHDE1, and DESMOND KENNY4 1Office of Laboratory Informatics, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark; 2Drug Control Centre, London University, King’s College, London, UK; 3IMIM, Dr. Aiguader 80, Barcelona, Spain; 4Dept. of Clinical Biochemistry, Our Lady’s Hospital for Sick Children, Crumlin, Dublin 12, Ireland #§The combined Memberships of the Committee and the Commission (C-NPU) during the preparation of this report (1994–1996) were as follows: Chairman: H. Olesen (Denmark, 1989–1995); D. Kenny (Ireland, 1996); Members: X. Fuentes-Arderiu (Spain, 1991–1997); J. G. Hill (Canada, 1987–1997); D. Kenny (Ireland, 1994–1997); H. Olesen (Denmark, 1985–1995); P. L. Storring (UK, 1989–1995); P. Soares de Araujo (Brazil, 1994–1997); R. Dybkær (Denmark, 1996–1997); C. McDonald (USA, 1996–1997). Please forward comments to: H. Olesen, Office of Laboratory Informatics 76-6-1, Copenhagen University Hospital (Rigshospitalet), 9 Blegdamsvej, DK-2100 Copenhagen, Denmark. E-mail: [email protected] Republication or reproduction of this report or its storage and/or dissemination by electronic means is permitted without the need for formal IUPAC permission on condition that an acknowledgment, with full reference to the source, along with use of the copyright symbol ©, the name IUPAC, and the year of publication, are prominently visible.
    [Show full text]
  • Aniline and Aniline Hydrochloride
    SOME AROMATIC AMINES AND RELATED COMPOUNDS VOLUME 127 This publication represents the views and expert opinions of an IARC Working Group on the Identification of Carcinogenic Hazards to Humans, which met remotely, 25 May–12 June 2020 LYON, FRANCE - 2021 IARC MONOGRAPHS ON THE IDENTIFICATION OF CARCINOGENIC HAZARDS TO HUMANS ANILINE AND ANILINE HYDROCHLORIDE 1. Exposure Characterization 1.1.2 Structural and molecular formulae, and relative molecular mass 1.1 Identification of the agent (a) Aniline 1.1.1 Nomenclature NH2 (a) Aniline Chem. Abstr. Serv. Reg. No.: 62-53-3 EC No.: 200-539-3 Molecular formula: C H N IUPAC systematic name: aniline 6 7 Relative molecular mass: 93.13 (NCBI, 2020a). Synonyms and abbreviations: benzenamine; phenylamine; aminobenzene; aminophen; (b) Aniline hydrochloride aniline oil. NH2 (b) Aniline hydrochloride Chem. Abstr. Serv. Reg. No.: 142-04-1 EC No.: 205-519-8 HCl IUPAC systematic name: aniline hydro - Molecular formula: C6H8ClN chloride Relative molecular mass: 129.59 (NCBI, Synonyms: aniline chloride; anilinium chlo- 2020b). ride; benzenamine hydrochloride; aniline. HCl; phenylamine hydrochloride; phenylam- monium chloride. 1.1.3 Chemical and physical properties of the pure substance Aniline is a basic compound and will undergo acid–base reactions. Aniline and its hydrochlo- ride salt will achieve a pH-dependent acid–base equilibrium in the body. 109 IARC MONOGRAPHS – 127 (a) Aniline Octanol/water partition coefficient (P): log Kow, 0.936, predicted median (US EPA, 2020b) Description: aniline appears as a yellowish Conversion factor: 1 ppm = 5.3 mg/m3 [calcu- to brownish oily liquid with a musty fishy lated from: mg/m3 = (relative molecular odour (NCBI, 2020a), detectable at 1 ppm 3 mass/24.45) × ppm, assuming temperature [3.81 mg/m ] (European Commission, 2016; (25 °C) and pressure (101 kPa)].
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Local Anesthetics
    Local Anesthetics Introduction and History Cocaine is a naturally occurring compound indigenous to the Andes Mountains, West Indies, and Java. It was the first anesthetic to be discovered and is the only naturally occurring local anesthetic; all others are synthetically derived. Cocaine was introduced into Europe in the 1800s following its isolation from coca beans. Sigmund Freud, the noted Austrian psychoanalyst, used cocaine on his patients and became addicted through self-experimentation. In the latter half of the 1800s, interest in the drug became widespread, and many of cocaine's pharmacologic actions and adverse effects were elucidated during this time. In the 1880s, Koller introduced cocaine to the field of ophthalmology, and Hall introduced it to dentistry Overwiev Local anesthetics (LAs) are drugs that block the sensation of pain in the region where they are administered. LAs act by reversibly blocking the sodium channels of nerve fibers, thereby inhibiting the conduction of nerve impulses. Nerve fibers which carry pain sensation have the smallest diameter and are the first to be blocked by LAs. Loss of motor function and sensation of touch and pressure follow, depending on the duration of action and dose of the LA used. LAs can be infiltrated into skin/subcutaneous tissues to achieve local anesthesia or into the epidural/subarachnoid space to achieve regional anesthesia (e.g., spinal anesthesia, epidural anesthesia, etc.). Some LAs (lidocaine, prilocaine, tetracaine) are effective on topical application and are used before minor invasive procedures (venipuncture, bladder catheterization, endoscopy/laryngoscopy). LAs are divided into two groups based on their chemical structure. The amide group (lidocaine, prilocaine, mepivacaine, etc.) is safer and, hence, more commonly used in clinical practice.
    [Show full text]
  • A Comprehensive Guide Ram Roth Elizabeth A.M. Frost Clifford Gevirtz
    The Role of Anesthesiology in Global Health A Comprehensive Guide Ram Roth Elizabeth A.M. Frost Cli ord Gevirtz Editors Carrie L.H. Atcheson Associate Editor 123 The Role of Anesthesiology in Global Health Ram Roth • Elizabeth A.M. Frost Clifford Gevirtz Editors Carrie L.H. Atcheson Associate Editor The Role of Anesthesiology in Global Health A Comprehensive Guide Editors Ram Roth Elizabeth A.M. Frost Department of Anesthesiology Department of Anesthesiology Icahn School of Medicine at Mount Sinai Icahn School of Medicine at Mount Sinai New York , NY , USA New York , NY , USA Clifford Gevirtz Department of Anesthesiology LSU Health Sciences Center New Orleans , LA , USA Associate Editor Carrie L.H. Atcheson Oregon Anesthesiology Group Department of Anesthesiology Adventist Medical Center Portland , OR , USA ISBN 978-3-319-09422-9 ISBN 978-3-319-09423-6 (eBook) DOI 10.1007/978-3-319-09423-6 Springer Cham Heidelberg New York Dordrecht London Library of Congress Control Number: 2014956567 © Springer International Publishing Switzerland 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. Exempted from this legal reservation are brief excerpts in connection with reviews or scholarly analysis or material supplied specifi cally for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work.
    [Show full text]
  • Nitrosamines EMEA-H-A5(3)-1490
    25 June 2020 EMA/369136/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Procedure under Article 5(3) of Regulation EC (No) 726/2004 Nitrosamine impurities in human medicinal products Procedure number: EMEA/H/A-5(3)/1490 Note: Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents Table of contents ...................................................................................... 2 1. Information on the procedure ............................................................... 7 2. Scientific discussion .............................................................................. 7 2.1. Introduction......................................................................................................... 7 2.2. Quality and safety aspects ..................................................................................... 7 2.2.1. Root causes for presence of N-nitrosamines in medicinal products and measures to mitigate them............................................................................................................. 8 2.2.2. Presence and formation of N-nitrosamines
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Drug and Medication Classification Schedule
    KENTUCKY HORSE RACING COMMISSION UNIFORM DRUG, MEDICATION, AND SUBSTANCE CLASSIFICATION SCHEDULE KHRC 8-020-1 (11/2018) Class A drugs, medications, and substances are those (1) that have the highest potential to influence performance in the equine athlete, regardless of their approval by the United States Food and Drug Administration, or (2) that lack approval by the United States Food and Drug Administration but have pharmacologic effects similar to certain Class B drugs, medications, or substances that are approved by the United States Food and Drug Administration. Acecarbromal Bolasterone Cimaterol Divalproex Fluanisone Acetophenazine Boldione Citalopram Dixyrazine Fludiazepam Adinazolam Brimondine Cllibucaine Donepezil Flunitrazepam Alcuronium Bromazepam Clobazam Dopamine Fluopromazine Alfentanil Bromfenac Clocapramine Doxacurium Fluoresone Almotriptan Bromisovalum Clomethiazole Doxapram Fluoxetine Alphaprodine Bromocriptine Clomipramine Doxazosin Flupenthixol Alpidem Bromperidol Clonazepam Doxefazepam Flupirtine Alprazolam Brotizolam Clorazepate Doxepin Flurazepam Alprenolol Bufexamac Clormecaine Droperidol Fluspirilene Althesin Bupivacaine Clostebol Duloxetine Flutoprazepam Aminorex Buprenorphine Clothiapine Eletriptan Fluvoxamine Amisulpride Buspirone Clotiazepam Enalapril Formebolone Amitriptyline Bupropion Cloxazolam Enciprazine Fosinopril Amobarbital Butabartital Clozapine Endorphins Furzabol Amoxapine Butacaine Cobratoxin Enkephalins Galantamine Amperozide Butalbital Cocaine Ephedrine Gallamine Amphetamine Butanilicaine Codeine
    [Show full text]
  • Sds – Safety Data Sheet
    Effective Date: 02/02/16 Replaces Revision: 01/01/13, 12/22/10 NON-EMERGENCY TELEPHONE 24-HOUR CHEMTREC EMERGENCY TELEPHONE 610-866-4225 800-424-9300 SDS – SAFETY DATA SHEET 1. Identification Product Identifier: N, N – DIMETHYLANILINE Synonyms: Xylidine; N,N-Dimethylbenzenamine; Benzenamine,N,N-Dimethyl-; Dimethylphenylamine Chemical Formula: C6H5N(CH3)2 Recommended Use of the Chemical and Restrictions On Use: Laboratory Reagent Manufacturer / Supplier: Puritan Products; 2290 Avenue A, Bethlehem, PA 18017 Phone: 610-866-4225 Emergency Phone Number: 24-Hour Chemtrec Emergency Telephone 800-424-9300 2. Hazard(s) Identification Classification of the Substance or Mixture: Flammable liquids (Category 4) Acute toxicity, Oral (Category 3) Acute toxicity, Inhalation (Category 3) Acute toxicity, Dermal (Category 3) Skin irritation (Category 3) Eye irritation (Category 2A) Carcinogenicity (Category 2) Acute aquatic toxicity (Category 2) Chronic aquatic toxicity (Category 2) Risk Phrases: Symbol: T, N R23/24/25: Toxic by inhalation, in contact with skin and if swallowed. R40: Limited evidence of a carcinogenic effect. R51/ 53: Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. Label Elements: Trade Name: N, N – DIMETHYLANILINE Signal Word: Danger N, N - DIMETHYLANILINE Page 1 of 6 Hazard Statements: H227: Combustible liquid. H301 + H311: Toxic if swallowed or in contact with skin. H316: Causes mild skin irritation. H319: Causes serious eye irritation. H331: Toxic if inhaled. H351: Suspected of causing cancer. H411: Toxic to aquatic life with long lasting effects. Precautionary Statements: P261: Avoid breathing dust / fume / gas / mist / vapors / spray. P273: Avoid release to the environment. P280: Wear protective gloves / protective clothing.
    [Show full text]